Helicobacter pylori infection, but not low-dose aspirin, results in a local reduction of the secretory leukocyte protease inhibitor in gastroduodenal mucosa

Helicobacter

Volumn 11, Issue 1, 2006, Pages 31-38

  Wex, Thomas ^a,b,c   Ye, Siying ^b   Treiber, Gerhard ^a   Vieth, Michael ^c   Roessner, Albert ^c   Malfertheiner, Peter ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gastritis; Helicobacter pylori; Low dose aspirin; SLPI

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UREASE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DUODENUM BIOPSY; DUODENUM MUCOSA; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERADICATION THERAPY; FEMALE; GASTRITIS; GASTRODUODENOSCOPY; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE SIZE; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH MUCOSA; UREA BREATH TEST;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL MUCOSA; MALE; PROSPECTIVE STUDIES; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR;

HELICOBACTER PYLORI;

EID: 33644592342     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.0083-8703.2006.00376.x     Document Type: Article

References (37)

1. McCarthy DM Helicobacter pylori infection and gastroduodenal injury by nonsteroidal anti-inflammatory drugs Scand J Gastroenterol Suppl 1991 187 91 7
2. Laine L Review article: the effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury Aliment Pharmacol Ther 2002 Suppl. 1 34 9
3. Halter F Tarnawski AS Schmassmann A Peskar BM Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives Gut 2001 49 443 53
4. Davies NM Jamali F COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter J Pharm Pharm Sci 2004 7 332 6
5. Blaser MJ Helicobacter pylori and the pathogenesis of gastroduodenal inflammation J Infect Dis 1990 161 626 33
6. Sepulveda AR Coelho LG Helicobacter pylori and gastric malignancies Helicobacter 2002 7 37 42
7. Naumann M Crabtree JE Helicobacter pylori-induced epithelial cell signaling in gastric carcinogenesis Trends Microbiol 2004 12 29 36
8. Segal ED Falkow S Tompkins LS Helicobacter pylori attachment to gastric cells induces cytoskeletal rearrangements and tyrosine phosphorylation of host cell proteins Proc Natl Acad Sci U S A 1996 93 1259 64
9. Lindholm C Quiding-Jarbrink M Lonroth H Svennerholm AM Induction of chemokine and cytokine responses by Helicobacter pylori in human stomach explants Scand J Gastroenterol 2001 36 1022 9
10. Wex T Treiber G Nilius M Vieth M Roessner A Malfertheiner P Helicobacter pylori-mediated gastritis induces local down-regulation of secretory leukocyte protease inhibitor in the antrum Infect Immun 2004 72 2383 5
11. Wex T Sokic-Milutinovic A Todorovic V Milosavljevic T Malfertheiner P The down-regulation of secretory leukocyte protease inhibitor (SLPI) expression in gastric mucosa is a general phenomenon in Helicobacter pylori-related gastroduodenal diseases Dig Dis 2005 22 390 5
12. Potempa J Korzus E Travis J The serpin superfamily of proteinase inhibitors: structure, function, and regulation J Biol Chem 1994 269 15957 60
13. Hiemstra PS Maassen RJ Stolk J Heinzel-Wieland R Steffens GJ Dijkman JH Antibacterial activity of antileukoprotease Infect Immun 1996 64 4520 4
14. Ashcroft GS Lei K Jin W Longenecker G Kulkarni AB Greenwell-Wild T Hale-Donze H McGrady G Song XY Wahl SM Secretory leukocyte protease inhibitor mediates nonredundant functions necessary for normal wound healing Nat Med 2000 6 1147 53
15. Zhu J Nathan C Jin W et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair Cell 2002 111 867 78
16. Taggart CC Greene CM McElvaney NG O'Neill SJ Secretory leucoprotease inhibitor prevents LPS-induced Ikappa Balpha degradation without affecting phosphorylation or ubiquitination J Biol Chem 2002 277 33648 53
17. Greene CM McElvaney NG O'Neill SJ Taggart CC Secretory leucoprotease inhibitor impairs toll-like receptor 2- and 4-mediated responses in monocytic cells Infect Immun 2004 72 3684 7
18. Henriksen PA Hitt M Xing Z Wang J Haslett C Riemersma RA Webb DJ Kotelevtsev YV Sallenave JM Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli J Immunol 2004 172 4535 44
19. Devoogdt N Hassanzadeh Ghassabeh G Zhang J Brys L De Baetselier P Revets H Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells Proc Natl Acad Sci U S A 2003 100 5778 82
20. Devoogdt N Revets H Ghassabeh GH DE Baetselier P Secretory leukocyte protease inhibitor in cancer development Ann NY Acad Sci 2004 1028 380 9
21. Tsukishiro S Suzumori N Nishikawa H Arakawa A Suzumori K Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis Gynecol Oncol 2005 96 516 9
22. Sallenave JM The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease Respir Res 2000 1 87 92
23. Duits LA Tjabringa GS Aarts NJ van't Wout JW Hiemstra PS Nibbering PH van Dissel JT Plasma secretory leukocyte protease inhibitor in febrile patients Clin Microbiol Infect 2003 9 605 13
24. Grobmyer SR Barie PS Nathan CF et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia Crit Care Med 2000 28 1276 82
25. Wang X Li X Xu L Zhan Y Yaish-Ohad S Erhardt JA Barone FC Feuerstein GZ Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury Mol Pharmacol 2003 64 833 40
26. Dixon MF Genta RM Yardley JH Correa P Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994 Am J Surg Pathol 1996 20 1161 81
27. 13C-urea breath test for pre- and post-treatment diagnosis of Helicobacter pylori infection in the routine clinical setting Am J Gastroenterol 1999 94 2100 4
28. Malfertheiner P Enrique D Heckenmuller H Neubrand M Fischer HP Sauerbruch T Modified rapid urease test for detection of Helicobacter pylori infection Eur J Gastroenterol Hepatol 1996 8 53 6
29. Wex T Treiber G Lendeckel U Malfertheiner P A two-step method for the extraction of high-quality RNA from endoscopic biopsies Clin Chem Lab Med 2003 41 1033 7
30. Si-Tahar M Merlin D Sitaraman S Madara JL Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells Gastroenterology 2000 118 1061 71
31. Taha AS Faccenda E Angerson WJ Balsitis M Kelly RW Gastric epithelial anti-microbial peptides: histological correlation and influence of anatomical site and peptic ulcer disease Dig Liver Dis 2005 37 51 6
32. Taggart CC Lowe GJ Greene CM Mulgrew AT O'Neill SJ Levine RL McElvaney NG Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor J Biol Chem 2001 276 33345 52
33. Tam EM Morrison CJ Wu YI Stack MS Overall CM Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates Proc Natl Acad Sci U S A 2004 101 6917 22
34. Koyama S Significance of cell-surface expression of matrix metalloproteinases and their inhibitors on gastric epithelium and infiltrating mucosal lymphocytes in progression of Helicobacter pylori-associated gastritis Scand J Gastroenterol 2004 39 1046 53
35. Dohchin A Suzuki JI Seki H Masutani M Shiroto H Kawakami Y Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma Cancer 2000 89 482 7
36. Farinati F Herszenyi L Plebani M et al. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis Carcinogenesis 1996 17 2581 7
37. Buhling F Peitz U Kruger S Kuster D Vieth M Gebert I Roessner A Weber E Malfertheiner P Wex T Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa Biol Chem 2004 385 439 45